The FGFR2 Variant rs13387042 is Associated With Breast Cancer Risk: A Meta-Analysis and Systematic Review
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.03.009 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Weining Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Life Sciences, Warwick University, Coventry, United Kingdom. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Predisposition to Disease, Receptor, Fibroblast Growth Factor, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: The association of FGFR2-rs13387042 polymorphism with breast cancer (BC) susceptibility in women remains inconclusive due to varying reports. In this study, we conducted a meta-analysis to explore the relationship between FGFR2-rs13387042 polymorphism and susceptibility to BC. METHODS: Relevant literature were acquired through searches across multiple databases. Odds ratio (OR) values were pooled to assess the risk of BC for different alleles and genotypes. The heterogeneity among the included literature was evaluated. Sensitivity analysis was used to verify the stability of the results. Egger's linear regression test was used to assess the significance of publication bias of the included literature. RESULTS: A total of 17 publications were included, encompassing 122,607 cases and 175,966 controls. There was significantly increased risk of BC for allele A compared with G (OR = 1.15, 95% CI = 1.14-1.67, P < .001), genotype AA compared with GG (OR = 1.34, 95% CI = 1.29-1.38, P < .001), and genotype GA compared with GG (OR = 1.19, 95% CI = 1.12-1.26, P < .001). Both Egger's test and funnel plot indicated the presence of publication bias. After adjusting potential publication bias by the trim-and-fill method, the comparison of allele A versus G (OR = 1.15, 95% CI = 1.13-1.17, P < .001), genotype AA versus GG (OR = 1.32, 95% CI = 1.28-1.37, P < .001), and genotype GA versus GG (OR = 1.15, 95% CI = 1.09-1.22, P < .001) remained statistically significant. In various subgroups, the allele A showed significantly higher risk of BC upon allele G in estrogen receptor (ER) positive BC, ER negative BC, progesterone receptor (PR) positive BC, PR negative BC, triple-negative BC, pathological grade I BC, grade II BC, and grade III breast cancer. The subsequent sensitivity analysis suggested the above findings stable and reliable. CONCLUSION: In this study, we found that the allele A of the FGFR2-rs13387042 polymorphism is associated with increased risk of developing breast cancer. This study underscores its potential as a genetic marker for personalized risk assessment and targeted interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Life Sciences, Warwick University, Coventry, United Kingdom.
- Department of Pathology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China.
- Department of Thoracic Surgery, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China.
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China; Department of Thoracic Surgery, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China.
- Department of Surgical Oncology, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China; Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China. Electronic address: linmengbo0@hotmail.c…
Zitieren
APA
Pan, W., Cheng, H., Zhang, J., Yang, Z., & Lin, M. (2024). The FGFR2 Variant rs13387042 is Associated With Breast Cancer Risk: A Meta-Analysis and Systematic Review. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.03.009
Vancouver
Pan W, Cheng H, Zhang J, Yang Z, Lin M. The FGFR2 Variant rs13387042 is Associated With Breast Cancer Risk: A Meta-Analysis and Systematic Review. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.03.009
BibTeX
@article{Pan2024,
author = {Pan, Weining and Cheng, Hui and Zhang, Juan and Yang, Zijie and Lin, Mengbo},
title = {The FGFR2 Variant rs13387042 is Associated With Breast Cancer Risk: A Meta-Analysis and Systematic Review},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.03.009}
}
EUVIMED